Less than a decade since the discovery of CADM1, loss of its expression by promoter hypermethylation or loss of heterozygosity (LOH) has been reported in a wide variety of tumor types ( Additional file2: Figure S1) and frequently correlates with advanced tumor stage (poor prognosis) and metastasis[3]. Here, CADM1 is linked to neoplasm.